Trial reportJournal of thrombosis and haemostasis : JTH2020
Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications.
Trial report in Journal of thrombosis and haemostasis : JTH, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications.Journal of thrombosis and haemostasis : JTH · 2020Trial
- Design of a modified platelet immunofluorescence test to assess platelet-reactive antibody burden and its association with platelet functional exhaustion and clinical features in chronic immune thrombocytopenia.British journal of haematology · 2026Article
- Real-world investigation of platelet apoptosis for mechanistic insights into severe immune thrombocytopenia and bleeding.Research and practice in thrombosis and haemostasis · 2026Article
- When GPVI Goes Rogue: Pathogenesis and Therapeutic Horizons in ITP.Expert reviews in molecular medicine · 2026Review
- Prognostic Re-evaluation of Antinuclear Antibodies in Childhood Immune Thrombocytopenia.TH open : companion journal to thrombosis and haemostasis · 2026Article
- When the victim becomes the villain: Platelets as drivers of immune dysregulation in ITP.Journal of translational autoimmunity · 2025Review
- The Prognostic Value of Platelet Kinetics Assessment in Pediatric Chronic Idiopathic Thrombocytopenic Purpura.Diagnostics (Basel, Switzerland) · 2025Article
- Clinical and Laboratory Characteristics of Children with Chronic Idiopathic Thrombocytopenic Purpura.Diagnostics (Basel, Switzerland) · 2025Article
- Desialylation and Apoptosis in Immune Thrombocytopenia: Implications for Pathogenesis and Treatment.Current issues in molecular biology · 2024Review
- Interleukin (IL)-1B and IL-1 receptor antagonist gene polymorphisms in children with primary immune thrombocytopenia.Clinical and experimental pediatrics · 2024Article
- Pathogenesis of refractory ITP: Overview.British journal of haematology · 2023Review
- Downregulation of ADAM17 in pediatric immune thrombocytopenia impairs proplatelet formation.BMC pediatrics · 2022Article
- Biological stratification of clinical disease courses in childhood immune thrombocytopenia.Journal of thrombosis and haemostasis : JTH · 2021Article
- Diagnostic and Predictive Contribution of Autoantibodies Screening in a Large Series of Patients With Primary Immunodeficiencies.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-platelet antibody testing may be useful for the diagnosis and management of childhood immune thrombocytopenia (ITP).
objectivesHere we aimed to assess the prevalence and prognostic significance of anti-platelet glycoprotein-specific IgM and IgG antibodies.
methodsChildren with newly diagnosed ITP were included at diagnosis and randomized to an intravenous immunoglobulins (IVIg) or careful observation group (TIKI trial). In this well-defined and longitudinally followed cohort (N = 179), anti-platelet glycoprotein-specific IgM and IgG antibodies were determined by monoclonal antibody-immobilization of platelet antigens.
resultsThe dominant circulating anti-platelet antibody class in childhood ITP was IgM (62% of patients); but IgG antibodies were also found (10%). Children without IgM platelet antibodies were older and more often female. There was weak evidence for an association between IgM anti-GP IIb/IIIa antibodies and an increased bleeding severity (P = .03). The IgM and IgG anti-platelet responses partially overlapped, and reactivity was frequently directed against multiple glycoproteins. During 1-year follow-up, children with IgM antibodies in the observation group displayed a faster platelet recovery compared to children without, also after adjustment for age and preceding infections (P = 7.1 × 10
conclusionsTesting for circulating anti-platelet antibodies may be helpful for the clinical prognostication and the guidance of treatment decisions in newly diagnosed childhood ITP. Our data suggest that the development of even more sensitive tests may further improve the clinical value of antibody testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.